Novo Nordisk's China Filing Lands Amid a Deeper Debate Over Its Growth Trajectory

Novo's oral Wegovy gets China review, but shares fall 2.8% as analysts weigh Lilly competition and patent expiry risks.

The acceptance of a regulatory application rarely moves markets on its own. But when China's drug authority agreed to review the oral version of Wegovy this week, it landed at a delicate moment for Novo Nordisk—one where the company is simultaneously advancing a pill-based strategy for the world's second-largest pharma market while fending off mounting skepticism about its medium-term growth prospects.

The Danish drugmaker's shares fell 2.8 percent on Thursday to 39.47 euros, extending a stretch of weakness that has left the stock 28 percent below its 52-week high of 54.86 euros. The decline came despite the China news, a reaction that underscores how investors are weighing pipeline progress against competitive pressures from Eli Lilly and questions about what happens when the current blockbuster patents begin to expire.

A Two-Track Strategy Takes Shape

The China filing is the clearest signal yet that Novo Nordisk is betting on the tablet as a mass-market product rather than relying solely on injectables. The company has moved quickly on multiple fronts: announcing the pill's arrival in Germany, launching the OASIS-5 late-stage study testing lower maintenance doses in 450 overweight adults without diabetes over 60 weeks, and now pursuing approval in China—a market with hundreds of millions of potential patients.

CEO Mike Doustdar framed the competitive dynamic with Eli Lilly roughly two weeks ago as anything but a winner-take-all contest. The China acceptance gives that statement tangible weight. The strategy rests on the premise that market access and scale will ultimately matter more than the molecule debate itself.

The company is also building out a broader ecosystem around weight loss. Lexicon Pharmaceuticals received a third milestone payment of $10 million on Monday after reaching a key dosing step in the Phase 1 program for LX9851. A separate collaboration with Novonesis is exploring microbiome-based products as adjuncts to GLP-1 medications, though results aren't expected until the second half of 2027. Both initiatives remain far from commercialization, but they illustrate a portfolio approach rather than a single-product bet.

The Analyst Divide Widens

The China filing didn't stop Deutsche Bank from downgrading the stock to Sell from Hold, cutting its price target by 9 percent to 265 Danish kroner. It's the bank's second downgrade of Novo this year—in February, it moved the stock to Hold from Buy following disappointing trial data.

The bear case centers on the medium-term outlook. Ziltivekimab is now viewed as effectively out of the running, the anticipated boost from Medicare prescriptions looks limited, and there's the looming threat of a revenue cliff once current blockbuster patents lapse. That combination has analysts questioning whether the company can return to robust growth by 2027.

The most recent quarterly report looked solid at first glance. Novo raised its full-year guidance earlier than expected, now projecting earnings and revenue in a range of zero to minus 6 percent year-over-year—a marked improvement over the previously targeted minus 12 to minus 4 percent. But investors focused on two blemishes: a slight decline in Wegovy pill sales and a setback in the study of the follow-on obesity treatment.

Not everyone shares Deutsche Bank's pessimism. JPMorgan raised its price target following the same earnings report, highlighting how fractured analyst opinion has become. The broader consensus remains moderately positive: 37 analysts average a price target of $51.19 with a 68 percent buy rating. The company still commands a market capitalization above $200 billion, though the stock trades well off its January peak.

A Production Setback in the Background

Not all recent news has been about the pipeline. Scholar Rock withdrew its European application for a spinal muscular atrophy treatment last week, citing plans to switch manufacturing facilities after problems at a Novo Nordisk plant in Bloomington, Indiana. The incident is minor relative to the China filing, but it serves as a reminder that Novo Nordisk's role as a contract manufacturer for third parties carries its own risks.

What Comes Next

The near-term question is whether a single regulatory acceptance in China can shift the sentiment that has built up since the stock's January peak. The answer likely depends less on any one announcement than on the cumulative weight of the company's efforts—the pill, the studies, the partnerships, the milestones.

For Novo Nordisk, the path forward involves convincing investors that the pipeline can bridge the gap before the patent cliff arrives. The China filing is a step in that direction, but the market's muted reaction suggests the skepticism won't lift until accepted applications become actual approvals—and until the growth narrative for 2027 and beyond becomes clearer.